According to researchers at the Perelman School of Medicine at the University of Pennsylvania patients of Atrial fibrillation with VHD receiving apixaban had a lower risk for ischemic stroke or.
Stroke Clot Risk Halved When Apixaban Taken Versus Rivaroxaban miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
The new study showed apixaban is superior to rivaroxaban against stroke or systemic embolism in patients with atrial fibrillation and valvular heart disease
March 31, 2021
Helping to fill an evidence gap, a retrospective review of a large database of US commercial health claims indicates that in patients with valvular atrial fibrillation (AF), direct oral anticoagulants (DOACs) are associated with lower risks of stroke, systemic embolism, and major bleeding compared with warfarin.
The findings shed light on a topic that has proved confusing for clinicians due to the different definitions of “valvular heart disease” used across clinical trials and guidelines. Patients with both AF and valve disease were excluded from the randomized trials that led to the approval of apixaban (Eliquis; Bristol-Myers Squibb), edoxaban (Savaysa; Daiichi-Sankyo), rivaroxaban (Xarelto; Bayer/Janssen), and dabigatran (Pradaxa; Boehringer Ingelheim) in the United States, so their safety and efficacy in this setting remains unclear.
DOACs Top Warfarin in Real-World Valvular Heart Disease Patients medpagetoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medpagetoday.com Daily Mail and Mail on Sunday newspapers.